Antitumor activities of L-MTP-PE (Liposome entrapped myuramyl tripeptide
phosphatidylethanolamine) in the combination treatment with chemo- or
immune-therapeutic antitumor agents against various syngeneic tumors were
tested.Against Meth A fibrosarcoma solid tumor system, L-MTP-PE showed slight but
statistically significant elongation of survival days against 5-FU monotherapy
in spite of its non-effect on tumor growth, when combined with 5-FU. Against
liver metastasis model of M5076 carcinoma, L-MTP-PE showed a tendency of
elongation of survival days by its single drug treatment, however, elongation
with statistical significance was observed in the combination treatment with
5-FU in comparison with control group.These data suggest that L-MTP-PE seems to elongate the survival days of the solid
tumor bearing mice and the liver metastasis model basically due to its saving
effect on chemotherapeutic drug-induced immunosuppression. In the combination
with an immunotherapeutic agent in mice, TNF production induced by another
biological response modifier OK-432 was potentiated when primed with L-MTP-PE.
L-MTP-PE also potentiate the antitumor effect of OK-432 possibly through the
enhanced production of TNF-α. Combination of L-MTP-PE and OK-432 is
considered to be a candidate for a new treatment model for cancer.